Analysts Offer Predictions for CMPS FY2025 Earnings

COMPASS Pathways plc (NASDAQ:CMPS) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of COMPASS Pathways in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan expects that the company will post earnings per share of ($2.05) for the year. The consensus estimate for COMPASS Pathways’ current full-year earnings is ($2.33) per share.

CMPS has been the subject of several other reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $18.00 price objective on shares of COMPASS Pathways in a research note on Wednesday, January 15th. Maxim Group dropped their price objective on COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating for the company in a report on Friday, November 1st. Finally, HC Wainwright decreased their target price on COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating for the company in a report on Friday, November 1st. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, COMPASS Pathways currently has a consensus rating of “Buy” and a consensus target price of $33.60.

COMPASS Pathways Trading Up 4.3 %

NASDAQ:CMPS opened at $3.64 on Wednesday. The firm has a market capitalization of $249.05 million, a P/E ratio of -1.65 and a beta of 2.27. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.15. The company has a fifty day moving average of $4.24 and a 200 day moving average of $5.83. COMPASS Pathways has a 52 week low of $3.16 and a 52 week high of $12.75.

COMPASS Pathways (NASDAQ:CMPS) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.04. During the same period in the previous year, the business posted ($0.67) EPS.

Hedge Funds Weigh In On COMPASS Pathways

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Polar Asset Management Partners Inc. increased its stake in shares of COMPASS Pathways by 83.3% in the 3rd quarter. Polar Asset Management Partners Inc. now owns 567,600 shares of the company’s stock worth $3,576,000 after acquiring an additional 258,000 shares in the last quarter. Logos Global Management LP increased its stake in shares of COMPASS Pathways by 349.3% during the second quarter. Logos Global Management LP now owns 1,159,030 shares of the company’s stock valued at $7,001,000 after purchasing an additional 901,050 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of COMPASS Pathways by 1,518.4% during the second quarter. Renaissance Technologies LLC now owns 263,800 shares of the company’s stock valued at $1,593,000 after purchasing an additional 247,500 shares in the last quarter. Sio Capital Management LLC lifted its holdings in shares of COMPASS Pathways by 211.7% during the third quarter. Sio Capital Management LLC now owns 914,639 shares of the company’s stock valued at $5,762,000 after purchasing an additional 621,222 shares during the last quarter. Finally, Walleye Capital LLC bought a new stake in shares of COMPASS Pathways in the 3rd quarter worth approximately $2,126,000. Hedge funds and other institutional investors own 46.19% of the company’s stock.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.